top of page

Viral/Bacterial Infections

Conventional wisdom teaches that blood platelets function primarily to maintain hemostasis and thrombosis, whereas white blood cells are responsible for immune defense. While platelets are recognized to contribute to the healing cascade following tissue injury, the clinical benefits of traditional PRP have yielded variable results largely related to the lack of standardization of both its preparation and route of administration. Recent scientific and clinical evidence has conclusively demonstrated the integral role with which platelets may contribute to the immune response in various types of infection, including bacterial and viral pathogens.

​

Please visit our Vimeo Channel to hear directly from patients and physicians about the power of TruDOSE™ Platelet Therapy in a wide range of physical conditions.

Viral/Bacterial Testimony

For more information about TruDOSE™ click one of the buttons below

I'd like to offer TruDOSE™ in my clinic

I'm a patient and would like more info about TruDOSE™

©2024 TruDOSE™ Regenerative Technology

This web site is provided for educational and informational purposes about platelet therapy and does not constitute providing medical advice or professional services. All information provided on this website is from physician observational evidence or patient testimonials and not published clinical studies or clinical trials. As such, this information should not be used for diagnosing or treating a health problem or disease.  Individuals seeking personal medical advice should consult with a licensed physician. Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. No physician-patient relationship is created by this web site or its use.

​

As of June 1, 2021, the FDA updated their guidance on all “stem cell regenerative” therapies. The FDA makes a clear distinction on the use of autologous (from you) platelet therapies compared to donor cell therapies (cells not from you). The FDA1 states: “This guidance also does not apply to products that fall outside the definition of HCT/P in 21 CFR 1271.3(d). For example, platelet rich plasma (PRP, blood taken from an individual and given back to the same individual as platelet rich plasma) is not an HCT/P under 21 CFR Part 1271 because it is a blood product. Accordingly, FDA does not apply the criteria in 21 CFR 1271.10(a) to PRP, and PRP is outside the scope of this guidance.”

​

https://www.fda.gov/media/109176/download

bottom of page